Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of Salbutamol and Furosemide in TTN

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03208894
Recruitment Status : Completed
First Posted : July 6, 2017
Last Update Posted : July 6, 2017
Sponsor:
Information provided by (Responsible Party):
arshad khushdil, Armed Forces Hospital, Pakistan

Brief Summary:
to see the effects of slabutamol and IV furosemide in the treatment of transient tachypnea of newborn

Condition or disease Intervention/treatment Phase
Transient Tachypnea of the Newborn Drug: Furosemide Injection Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Role of Salbutamol and Furosemide in Transient Tachypnea of Newborn
Actual Study Start Date : November 1, 2016
Actual Primary Completion Date : May 30, 2017
Actual Study Completion Date : June 30, 2017


Arm Intervention/treatment
Experimental: with salbutamol Drug: Furosemide Injection
efficacy of salbutamol and furosemide in TTN
Other Name: salbutamol inhalation

Experimental: with furosemide Drug: Furosemide Injection
efficacy of salbutamol and furosemide in TTN
Other Name: salbutamol inhalation

Experimental: both furosemide and salbutamol Drug: Furosemide Injection
efficacy of salbutamol and furosemide in TTN
Other Name: salbutamol inhalation

No Intervention: no inervention



Primary Outcome Measures :
  1. duration of oxygen requiremment in neonates having TTN. [ Time Frame: upto 6 months ]
    neonates will be subjected to treatment with furosemide and sabutamol and the duration of oxygen dependecy will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 7 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • all newborn babies with clinically diagnosed TTN

Exclusion Criteria:

  • babies less than 34 weeks babies with congenital malformations and CHD

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03208894


Locations
Layout table for location information
Pakistan
Department of Pediatrics
Rawalpindi, Punjab, Pakistan, 68000
Military Hospital
Rawalpindi, Punjab, Pakistan, 68000
Sponsors and Collaborators
Armed Forces Hospital, Pakistan

Layout table for additonal information
Responsible Party: arshad khushdil, CONCULTANT PEDIATRICIAN, Armed Forces Hospital, Pakistan
ClinicalTrials.gov Identifier: NCT03208894     History of Changes
Other Study ID Numbers: TTN
First Posted: July 6, 2017    Key Record Dates
Last Update Posted: July 6, 2017
Last Verified: July 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Furosemide
Tachypnea
Transient Tachypnea of the Newborn
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Respiratory Distress Syndrome, Newborn
Lung Diseases
Infant, Premature, Diseases
Infant, Newborn, Diseases
Albuterol
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Diuretics
Natriuretic Agents
Sodium Potassium Chloride Symporter Inhibitors
Membrane Transport Modulators